Valeant Pharmaceuticals has added G. Mason Morfit, president of ValueAct Capital to its board of directors, effective immediately.
Morfit also currently serves on the board of directors for Microsoft and was former director of CR Bard, Immucor, Advanced Medical Optics and Solexa prior to his role at ValueAct Capital.
Morfit had originally served on Valeant’s board of directors between 2007 and 2014.
Michael Pearson, chairman and CEO of Valeant, said: “I am pleased to welcome Mason back to the Valeant board of directors.
“Although Mason has not officially been a part of the Valeant board for more than a year, I have continued to value his vision and guidance, and I believe his insights will be invaluable during this time.”